Regentis Biomaterials Ltd. RGNT
- Market cap
- $15.8M
- P/E
- —
Follow RGNT
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 5.75 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 7.70 |
High Price
|
|||
| — | — | — | — | — | — | — | — | 7 | 7 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | (4) | 5 | (14) |
EBT
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | (4) | 5 | (14) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | — | — | Depreciation | |||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | (23.81) | 1.72 | (24.16) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | (7.03) | (0.23) | (2.43) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | (7.03) | (0.23) | (2.43) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | (264.58) | (14.86) | 8.37 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | 0 | 3 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | (1) | (1) | (1) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | — | — | Capex | |||
| — | — | — | — | — | — | — | (1) | (1) | (1) |
FCF
|
|||
| — | — | — | — | — | — | — | (3) | (6) | 5 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | 8 | 5 | 1 |
Total Debt
|
|||
| — | — | — | — | — | — | — | 7 | 5 | (6) |
Net Debt
|
|||
| — | — | — | — | — | — | — | (46) | (41) | 5 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | 0.00% | 1,128.98% | (338.07%) |
ROA
|
|||
| — | — | — | — | — | — | — | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | — | — | — | — | 0.00% | (10.93%) | 75.31% |
ROE
|
|||
Regentis Biomaterials Ltd. peers in Medical Instruments & Supplies
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BNGO Bionano Genomics, Inc. | $19.9M | 0.0× | Compare |
| FEMY Femasys Inc. | $20.4M | 0.0× | Compare |
| RVP Retractable Technologies, Inc. | $20.5M | 0.0× | Compare |
| CUPR Cuprina Holdings (Cayman) Limited | $10.6M | — | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| LUCY Innovative Eyewear, Inc. | $8.0M | 0.0× | Compare |
| HBIO Harvard Bioscience, Inc. | $36.5M | 0.0× | Compare |
| MLSS Milestone Scientific, Inc. | $37.2M | 0.0× | Compare |
| NEPH Nephros Inc. | $45.0M | 27.2× | Compare |
Regentis Biomaterials Ltd. (RGNT) key facts
- Regentis Biomaterials Ltd. (RGNT) is a Medical Instruments & Supplies company in the Healthcare sector, listed on NYSE American.
- Regentis Biomaterials Ltd. reported a net loss of $13.6 million, or a loss of $24.16 per share, for fiscal 2025.
- As of September 25, 2026, RGNT traded at $1.98, a market capitalization of $15.8 million.
- Return on equity was 75.3% and debt-to-equity 0.00.
Regentis Biomaterials Ltd. (RGNT) Latest News
14 Sep
Regentis Biomaterials advances GelrinC as a new approach to knee cartilage repair. GelrinC advancement marks major product development progress in core cartilage repair operations.
11 Sep
Regentis Biomaterials Ltd. (RGNT) released financial results for the first half of 2026 and issued a corporate update. Half-year financial results and corporate updates typically produce moderate effects on near-term investor views and share price.
28 Aug
Regentis Biomaterials Ltd. advances GelrinC regenerative hydrogel, redefining cartilage repair. Core product advancement in cartilage repair signals major strategic progress likely to shift company trajectory and investor sentiment.
17 Aug
Regentis Biomaterials advances GelrinC via parallel US clinical trials and European commercial efforts. Parallel US clinical and European commercial progress for GelrinC signals major strategic expansion with potential to shift company trajectory and investor outlook.
14 Aug
Regentis Biomaterials (RGNT) strengthens manufacturing operations and intellectual property assets to target the global cartilage repair market. Manufacturing scale-up plus IP expansion represent major strategic moves that can shift competitive position and investor outlook.
3 Aug
Regentis Biomaterials advances regenerative solution addressing major unmet need in cartilage repair. Product advancement in core regenerative technology likely shifts competitive positioning and investor outlook.
30 Jul
Regentis Biomaterials (RGNT) targets the $3B cartilage repair market with its cell-free Gelrin C product. Targeting a multibillion-dollar market with a novel cell-free product signals major growth potential and strategic positioning.
27 Jul
Regentis Biomaterials (RGNT) stands to gain as regenerative medicine transforms the expanding $3B cartilage repair market. Regenerative medicine reshaping the $3B cartilage repair market positions RGNT for major gains in trajectory and investor sentiment.
20 Jul
Regentis Biomaterials Ltd. received a Japanese patent allowance for proprietary manufacturing technology, strengthening its global GelrinC intellectual property portfolio. Japanese patent allowance adds IP protection for GelrinC manufacturing but represents incremental rather than transformative progress for the company.
16 Jul
Regentis Biomaterials Ltd. (RGNT) received European approval for its next-generation GelrinC manufacturing process. European approval for upgraded GelrinC manufacturing directly supports expanded production capacity and market access.
15 Jul
Regentis Biomaterials received European regulatory approval for a new GelrinC manufacturing process that increases production yield by 400% ahead of European commercial launch. European approval for 400% higher yield manufacturing boosts Regentis production capacity and readiness for commercial launch.
17 Jun
Regentis Biomaterials Ltd. priced a $6.5 million private placement. The $6.5 million private placement supplies Regentis Biomaterials with fresh capital that supports ongoing operations and financial runway.
15 Jun
RGNT stock surged more than 850% in a single day. An 850% single-day surge indicates transformative events that can redefine company valuation and prospects.
8 Jun
Regentis Biomaterials Ltd. will begin European surgeon training for GelrinC in knee cartilage repair while accelerating commercial launch preparations. European surgeon training for GelrinC accelerates commercial launch and positions the company for expanded revenue and market entry.
Regentis Biomaterials advances European commercial launch plans for GelrinC. Progress toward GelrinC commercialization in Europe can support revenue growth and market expansion.
1 Jun
Regentis Biomaterials (RGNT) progresses its simplified cartilage repair platform toward key commercial milestones. Progress of cartilage repair platform toward commercial milestones signals major strategic advance with strong potential to reshape RGNT trajectory and investor outlook.
29 May
Regentis Biomaterials Ltd. (RGNT) develops an off-the-shelf regenerative implant to address a major gap in the knee cartilage repair market. RGNT's off-the-shelf implant targets a major unmet need in knee cartilage repair, potentially driving substantial growth and market penetration.
28 May
Regentis Biomaterials Ltd. (RGNT) is designated as a stock 'One to Watch'. Designation as 'One to Watch' may moderately lift RGNT visibility and short-term investor interest.
26 May
Regentis Biomaterials (RGNT) targets off-the-shelf solutions for knee cartilage repair. Off-the-shelf knee cartilage repair opportunity may moderately affect RGNT operations and positioning.
16 Apr
Regentis Biomaterials Ltd. (RGNT) advances commercial deployment of GelrinC in Europe through partnership with Humanitas Hospital and cartilage repair expert Prof. Elizaveta Kon. Strategic collaboration for GelrinC commercialization in Europe marks major market expansion step for RGNT.
17 Mar
Regentis Biomaterials Ltd. (RGNT) developed and patented a new solvent-free manufacturing process that increases GelrinC production yield by 400%. Patented solvent-free process quadrupling GelrinC yield enables major production scalability, cost reductions, and competitive edge.
24 Feb
Regentis Biomaterials Ltd. (RGNT) reported 2025 financial results and provided a business update. Financial results announcements and business updates drive significant shifts in market performance and investor sentiment.
Regentis Biomaterials Ltd. (RGNT) appoints new CFO and CBO as GelrinC nears commercial launch. New CFO/CBO appointments strengthen leadership for GelrinC's commercial launch, a pivotal growth milestone.
19 Feb
Regentis Biomaterials Ltd. (RGNT) appointed Dr. Galit Reske as Chief Medical Officer, bringing her strong track record of success in cartilage repair. Appointing a CMO with expertise in cartilage repair represents a major strategic enhancement to RGNT's leadership and clinical pipeline advancement.
17 Feb
Regentis Biomaterials Ltd. (RGNT) expands its European clinical site network to support ongoing commercial and clinical programs. Expanding European clinical sites accelerates commercialization and trial execution, significantly enhancing RGNT's growth and market positioning.
4 Feb
Regentis Biomaterials Ltd. has appointed Ori Gon as Chief Financial Officer and Chief Business Officer. This leadership change comes as the company progresses towards the commercial launch of its product GelrinC in Europe and advances its Phase III FDA trial in the United States. The appointment of a new CFO and CBO, alongside significant product developments, indicates a strategic shift that could greatly influence the company's market position and investor sentiment.
29 Jan
Regentis Biomaterials Ltd. is expanding its pivotal Phase III GelrinC clinical trial by adding several leading orthopedic centers across the U.S. This expansion aims to enhance the trial's reach and effectiveness, potentially accelerating the development of GelrinC as a treatment option in orthopedic applications. The expansion of the clinical site network is a significant strategic move that could enhance product development and market positioning.
20 Jan
Regentis Biomaterials Ltd. announced that its GelrinC product has shown significant success in regenerating cartilage structures in knee repair, as confirmed by MRI results using a validated, regulator-accepted method. This breakthrough suggests potential advancements in treating knee injuries and improving patient outcomes. The successful demonstration of GelrinC's efficacy in cartilage regeneration could significantly enhance Regentis' market position and investor sentiment.
6 Jan
Regentis Biomaterials Ltd. announced that its GelrinC product has demonstrated long-term durability in cartilage repair, validated through quantitative MOCART evaluation. This evaluation highlights GelrinC's effectiveness in promoting cartilage regeneration, potentially enhancing treatment options for patients with cartilage injuries. The long-term durability of GelrinC in cartilage repair could significantly enhance Regentis' competitive position and market sentiment.
18 Dec
Regentis Biomaterials Ltd. has been granted a new U.S. patent for GelrinC, an off-the-shelf regenerative cartilage repair product. This patent enhances the company's intellectual property portfolio and positions GelrinC for potential commercialization in the orthopedic market, addressing the growing demand for effective cartilage repair solutions. The new patent is likely to significantly impact Regentis Biomaterials' market positioning and future product offerings in the regenerative medicine sector.